G

Glenmark Pharmaceuticals Ltd
NSE:GLENMARK

Watchlist Manager
Glenmark Pharmaceuticals Ltd
NSE:GLENMARK
Watchlist
Price: 1 478.2 INR 0.69% Market Closed
Market Cap: 417.1B INR
Have any thoughts about
Glenmark Pharmaceuticals Ltd?
Write Note

Glenmark Pharmaceuticals Ltd
Short-Term Investments

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Glenmark Pharmaceuticals Ltd
Short-Term Investments Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Short-Term Investments CAGR 3Y CAGR 5Y CAGR 10Y
G
Glenmark Pharmaceuticals Ltd
NSE:GLENMARK
Short-Term Investments
â‚ą1.7B
CAGR 3-Years
6%
CAGR 5-Years
-9%
CAGR 10-Years
26%
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Short-Term Investments
â‚ą76.7B
CAGR 3-Years
53%
CAGR 5-Years
28%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Short-Term Investments
â‚ą77.9B
CAGR 3-Years
40%
CAGR 5-Years
36%
CAGR 10-Years
18%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Short-Term Investments
â‚ą117.4B
CAGR 3-Years
44%
CAGR 5-Years
21%
CAGR 10-Years
22%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Short-Term Investments
â‚ą3.3B
CAGR 3-Years
-11%
CAGR 5-Years
-10%
CAGR 10-Years
6%
M
Mankind Pharma Ltd
NSE:MANKIND
Short-Term Investments
â‚ą30B
CAGR 3-Years
32%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Glenmark Pharmaceuticals Ltd
Glance View

Market Cap
417.1B INR
Industry
Pharmaceuticals

Glenmark Pharmaceuticals Ltd. is a holding company, which engages in the development, manufacture and marketing of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra. The firm is primarily engaged in the business of developing, manufacturing and marketing of pharmaceutical products. The company focuses on manufacturing products across therapeutic areas of respiratory, dermatology and oncology. The company is involved in development of new chemical entities (NCEs) and new biological entities (NBEs). Its business segments include India, North America, Europe and Rest of the world. The company is focused on developing and marketing branded and generic formulations. Its products include FabiFlu, Ryaltris and Remo (Remogliflozin etabonate). Its FabiFlu is an antiviral medication to treat mild to moderate COVID-19. Its Ryaltris is a fixed-dose combination nasal spray of an antihistamine (olopatadine hydrochloride 665 microgram) and a steroid that treats symptoms associated with seasonal, as well as perennial allergic rhinitis. Its Remo is a sodium-glucose transport-2 (SGLT2) inhibitor for the type 2 diabetes.

GLENMARK Intrinsic Value
1 029.95 INR
Overvaluation 30%
Intrinsic Value
Price
G

See Also

What is Glenmark Pharmaceuticals Ltd's Short-Term Investments?
Short-Term Investments
1.7B INR

Based on the financial report for Jun 30, 2024, Glenmark Pharmaceuticals Ltd's Short-Term Investments amounts to 1.7B INR.

What is Glenmark Pharmaceuticals Ltd's Short-Term Investments growth rate?
Short-Term Investments CAGR 10Y
26%

Over the last year, the Short-Term Investments growth was 34%. The average annual Short-Term Investments growth rates for Glenmark Pharmaceuticals Ltd have been 6% over the past three years , -9% over the past five years , and 26% over the past ten years .

Back to Top